open access

Vol 44, No 6 (2010)
Submitted: 2010-03-03
Get Citation

Usefulness of the ALSAQ-5 scale in evaluation of quality of life in amyotrophic lateral sclerosis

Monika Gotqb-Janowska, Krystyna Honczarenko, Jan Stankiewicz
DOI: 10.1016/S0028-3843(14)60153-5
·
Neurol Neurochir Pol 2010;44(6):560-566.

open access

Vol 44, No 6 (2010)
Submitted: 2010-03-03

Abstract

Background and purpose

The evaluation of quality of life (QoL) is one of the most important factors in complex care of patients. The aim of the study was to estimate the usefulness of the shortened QoL-evaluating scale ALSAQ-5 in patients with amyotrophic lateral sclerosis and to establish the relationship between QoL and age, sex, duration of the disease, education and treatment.

Material and methods

Forty-four patients (24 males and 20 females) aged between 34 and 81 years (mean 58.9) were studied. The QoL was evaluated with the ALSAQ-40 and ALSAQ-5 scales. Patients could score between 0 and 100 pts in both scales (higher score denotes worse QoL). Mann-Whitney U-test, Wilcoxon test, Kolmogorov-Smirnov test and Spearman rank correlation coefficient were used for statistical analysis.

Results

The QoL was worsened by limited physical mobility (ALSAQ-40: 22.5–100 pts, mean 80.8; ALSAQ-5: 25–100 pts, mean 88.6), reduced daily living/independence (ALSAQ-40: 7.5–100 pts, mean 76.0; ALSAQ-5: 0–100 pts, mean 75), communication disturbances (ALSAQ-40: 17.9–100 pts, mean 75.2; ALSAQ-5: 0–100, mean 73.9), and emotional functioning (ALSAQ-40: 5–100 pts, mean 64.9; ALSAQ-5: 0–100, mean 73.9). Eating and drinking dysfunctions (ALSAQ-40: 0–100 pts, mean 66.3; ALSAQ-5: 0–100, mean 67) had a smaller influence on QoL.

Conclusions

Initial analysis shows that ALSAQ-5 is a sensitive and reliable instrument for the estimation of QoL of patients with amyotrophic lateral sclerosis. As there are no statistical differences in QoL estimation using ALSAQ-40 and ALSAQ-5, ALSAQ-5 seems to be more useful in clinical practice.

Abstract

Background and purpose

The evaluation of quality of life (QoL) is one of the most important factors in complex care of patients. The aim of the study was to estimate the usefulness of the shortened QoL-evaluating scale ALSAQ-5 in patients with amyotrophic lateral sclerosis and to establish the relationship between QoL and age, sex, duration of the disease, education and treatment.

Material and methods

Forty-four patients (24 males and 20 females) aged between 34 and 81 years (mean 58.9) were studied. The QoL was evaluated with the ALSAQ-40 and ALSAQ-5 scales. Patients could score between 0 and 100 pts in both scales (higher score denotes worse QoL). Mann-Whitney U-test, Wilcoxon test, Kolmogorov-Smirnov test and Spearman rank correlation coefficient were used for statistical analysis.

Results

The QoL was worsened by limited physical mobility (ALSAQ-40: 22.5–100 pts, mean 80.8; ALSAQ-5: 25–100 pts, mean 88.6), reduced daily living/independence (ALSAQ-40: 7.5–100 pts, mean 76.0; ALSAQ-5: 0–100 pts, mean 75), communication disturbances (ALSAQ-40: 17.9–100 pts, mean 75.2; ALSAQ-5: 0–100, mean 73.9), and emotional functioning (ALSAQ-40: 5–100 pts, mean 64.9; ALSAQ-5: 0–100, mean 73.9). Eating and drinking dysfunctions (ALSAQ-40: 0–100 pts, mean 66.3; ALSAQ-5: 0–100, mean 67) had a smaller influence on QoL.

Conclusions

Initial analysis shows that ALSAQ-5 is a sensitive and reliable instrument for the estimation of QoL of patients with amyotrophic lateral sclerosis. As there are no statistical differences in QoL estimation using ALSAQ-40 and ALSAQ-5, ALSAQ-5 seems to be more useful in clinical practice.

Get Citation

Keywords

quality of life, ALSAQ-5 scale, amyotrophic lateral sclerosis

About this article
Title

Usefulness of the ALSAQ-5 scale in evaluation of quality of life in amyotrophic lateral sclerosis

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 44, No 6 (2010)

Pages

560-566

DOI

10.1016/S0028-3843(14)60153-5

Bibliographic record

Neurol Neurochir Pol 2010;44(6):560-566.

Keywords

quality of life
ALSAQ-5 scale
amyotrophic lateral sclerosis

Authors

Monika Gotqb-Janowska
Krystyna Honczarenko
Jan Stankiewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl